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Quantifying collagen in mouse 
kidneys
S Sanna-Cherchi1
Identification of genes underlying quantitative trait loci (QTLs) 
represents a formidable task. Recent advances in the annotation of 
the mouse genome and the availability of newly developed mouse 
strains should boost gene discovery. Kato and colleagues report 
the localization of a QTL for collagen type I deposition in kidneys on 
mouse chromosome 2, representing the first step for the identification 
of a gene involved in interstitial fibrosis, an important pathway in 
progression to end-stage renal failure in many kidney disorders.
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During progression of kidney disease to 
end-stage renal failure, the accumulation 
of extracellular matrix components results 
in interstitial ﬁbrosis, which represents a 
common pathway to the majority of kid-
ney disorders, including conditions that 
primarily aﬀect glomeruli.1 The current 
paradigm is that, under pathological con-
ditions, tubular epithelial cells undergo an 
epithelial-to-mesenchymal transition, giv-
ing rise to myoﬁbroblasts, which in turn 
migrate through the basement membrane 
to the interstitium and start producing 
extracellular matrix components.2–4 In nor-
mal conditions, little or no type I collagen is 
synthesized, the more abundant one being 
type IV, but in pathological conditions, 
type I becomes actively produced, while 
type IV can increase, remain unmodiﬁed, 
or decrease.5,6 Therefore, understanding 
the determinants of extracellular matrix 
component deposition is of fundamental 
importance to the development of new 
therapeutic strategies to slow down or halt 
progression to renal failure.
Kato and colleagues7 (this issue) describe 
the identification of a quantitative trait 
locus (QTL) for renal collagen type I 
(COLI) deposition in a mouse model of 
proteinuria after albumin overload.
As a model, they performed a unilateral 
nephrectomy in 6-week-old mice under 
anesthesia, followed by 6 weeks of daily 
intraperitoneal administration of bovine 
serum albumin. Mice injected accord-
ing to this scheme developed proteinuria, 
interstitial inﬂammation, and progressive 
interstitial ﬁbrosis. Between days 14 and 
16 from bovine serum albumin injection, 
all animals were placed in metabolic cages 
for collection of urine and determination 
of 24-hour total protein excretion. At the 
end of the bovine serum albumin admin-
istration, the mice were sacriﬁced and kid-
neys harvested for quantiﬁcation of total 
COLI protein and for immunoﬂuorescence 
studies. The ﬁrst interesting ﬁnding is that, 
although proteinuria rose to the same 
level in diﬀerent mouse strains after daily 
injection of bovine serum albumin, COLI 
deposition was a strain-dependent phe-
nomenon, demonstrating a genetic eﬀect 
for this trait. While 129S1/svImJ (129) mice 
were placed at the extreme top of the dis-
tribution and C57BL/6J (B6) were placed 
at the extreme bottom, the other strains 
showed intermediate deposition. The out-
cross between 129 and B6 animals showed 
an F1 progeny with renal COLI deposition 
very similar to that of the parental B6 mice, 
thus implying QTLs with a major reces-
sive eﬀect in the 129 strain. The authors 
subsequently produced an adequately 
powered progeny of 120 backcross mice, 
breeding F1 animals with parental 129 as 
a mapping cohort. After a genome scan, 
they identiﬁed a suggestive QTL on chro-
mosome 2 that explains 9% of the genetic 
variance for this trait (Table 1).
The choice of Kato and colleagues7 to 
perform a mouse QTL project represents, 
for several reasons, a somewhat bold 
move. In fact, even if quantitative traits 
have been shown to be fairly amenable to 
mapping studies, the gene-discovery rate 
has been quite disappointing so far, as 
demonstrated by the fact that thousands 
of QTLs have been mapped with the use of 
rodent crosses but only a few dozen genes 
have been unequivocally identiﬁed (see 
Mouse Genome Informatics, http://www.
informatics.jax.org). The reasons for this 
so-far limited success are many and have 
been extensively reviewed by Flint and col-
leagues.8 In particular, among the genes 
that have been discovered, there is a skewed 
distribution toward genes with extremely 
large eﬀects on the trait (from 20% to 50% 
of variation). Moreover, the effect of a 
QTL is diﬃcult to estimate, because many 
linked variants underlying the same QTL 
can explain the total variance, thus making 
single eﬀects very small.9 Another problem 
is that in mendelian traits both pheno-
types and genotypes follow Mendel’s laws, 
whereas in quantitative traits only geno-
types do. As a result, establishing a clear 
correlate between a variant and the trait 
becomes more diﬃcult. To complicate the 
scenario, the phenotype-associated vari-
ants are only rarely major coding mutations 
(that is, null alleles or amino acid variants 
with profound eﬀects on a protein struc-
ture or function) and are more probably 
located in regulatory regions, less amenable 
to functional studies.
A typical QTL project is a very labor-
intensive, time- and resource-consuming 
project that can take several years to ‘see the 
light.’ It usually starts with the deﬁnition 
of the trait in terms of genetic background 
diﬀerence (kidney COLI deposition, in this 
case), selection of the appropriate breeding 
strategy, generation of a mapping cohort 
(100–300 animals, according to the esti-
mated eﬀect of the trait), and a genome-
wide scan for linkage to identify the QTL 
regions. This ﬁrst phase takes on average 
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1–2 years. The result is usually the detec-
tion of an area that is rarely smaller than 
20 cM (approximatively 40 Mb in mice). 
This approach has been proven to be pow-
erful and allowed the detection of robust 
and replicable signals for hundreds of 
traits, even with eﬀect size as low as 5%. 
The subsequent steps to identify the 
underlying genes classically require ﬁne 
mapping, candidate gene analysis, and 
functional studies to characterize the vari-
ant and eventually complementation stud-
ies. These subsequent steps can require 
more than 5 years with no guarantee as to 
the results. The usual way to narrow down 
a QTL interval is to generate congenic 
animals. A congenic animal is an artiﬁcial 
strain in which a locus is transferred from 
an inbred strain (donor) to another one 
(host) through a process of subsequent 
breedings, which usually takes ten genera-
tions (about 2 years). This process is per-
formed by selection at each generation of 
the animals that carry the locus of interest 
by phenotyping and/or genotyping for this 
locus and breeding back to the host inbred 
strain. At each generation the genomic con-
tent of the donor strain will decrease 50% 
on average, and after ten generations the 
new strain will have the target locus trans-
ferred on a background that will be about 
99.8% identical to that of the host inbred 
strain. The creation of a congenic animal 
can be speeded up by genotyping across the 
genome the animals at each generation and 
selecting for the next breeding the ones that 
have lost more than 50% of donor genome 
content (speed congenics). The creation of 
a congenic strain allows a deﬁnitive con-
firmation of a linkage peak and a more 
accurate estimate of the eﬀect size for the 
QTL, having removed the eﬀects of other 
QTLs in the genome of the donor strain 
that can act toward or against the pheno-
type of interest (background noise). More-
over, with a congenic animal, ﬁne mapping 
can narrow down the locus and eventually 
separate syntenic QTLs underlying a single 
large linkage interval. Although the crea-
tion of congenic animals is feasible and has 
been proven to allow ﬁne mapping of QTL 
intervals, it is laborious and time consum-
ing and helps in terms of mapping but not 
in terms of gene discovery. 
A good strategy to prioritize genes is to 
perform gene expression studies on con-
genic animals. In this way, when expression 
arrays are run for the whole transcriptome 
on RNA isolated from the tissue of interest 
at a speciﬁc developmental stage accord-
ing to the phenotype, the diﬀerences in 
expression between the congenic and the 
host inbred strain will be entirely attribut-
able to the QTL, thus giving direct insight 
into the gene or genes of interest or into 
the pathway involved in the determina-
tion of the phenotype (assuming that the 
QTL aﬀects gene expression). At this stage, 
approximately 6–8 years from the begin-
ning of the project, one can reasonably 
have dissected a QTL at a resolution of 
1–2 cM (2–4 Mb) and prioritized a hand-
ful of genes. Finding a genetic variant in 
one of the candidate genes is not enough to 
claim gene discovery. In contrast to human 
studies, ﬁnding independent mutations at 
the same gene is virtually impossible in 
inbred-mouse projects, which makes rig-
orous functional studies mandatory. Once 
a variant has been discovered and in vitro 
studies performed to show a functional 
eﬀect, complementation studies are usually 
still required by transgenic rescue and/or 
QTL-knockout interaction test.10
This common path for the identiﬁcation 
of genes underlying QTLs can take as long 
as 10 years of work, thousands of animals, 
and enormous costs for breeding, geno-
typing, expression arrays, and functional 
studies. These diﬃculties are reﬂected in 
the paucity of genes unequivocally identi-
ﬁed so far. Nevertheless, examples of success 
are present in the literature.11,12 Moreover, 
recent advances provide the possibility of 
speeding up and facilitating gene discovery, 
mainly at the mapping phase, potentially 
skipping the breeding to generate map-
ping cohorts and the congenic production. 
A potentially powerful tool is represented 
by the chromosomal substitution strains 
(CSSs). CSSs are animals in which every 
chromosome has been substituted by 
another one from a donor strain, by a breed-
ing strategy similar to that used for congenic 
generation. As a result, a CSS panel for a 
mouse strain pair is constituted by 22 ani-
mals (19 autosomes, 2 heterochromosomes, 
and 1 mitochondrial chromosome). CSSs 
allow the rapid localization of a QTL to a 
chromosome without any breeding or gen-
otyping, skipping the ﬁrst laborious steps 
for localization and congenic generation 
and starting immediately the ﬁne mapping 
phase. The main limitation is that ideally 
CSSs are required for every permutation of 
inbred strains (thousands of new strains), 
and few panels are now available (http://
www.informatics.jax.org).
Another promising strategy to ﬁnd genes 
for quantitative traits is in silico mapping. 
The main assumption underlying this strat-
egy is that most of the laboratory mice in 
use derive from a very limited number of 
founders. This makes the application of 
the genome-wide association study feasi-
ble. Moreover, the recent advances in the 
Table 1 | Glossary of the most common genetic terms used in mouse mapping projects
Term Definition
QTL Quantitative trait locus
Incross Mating between two members of the same inbred strain
Outcross Mating between two unrelated animals
Intercross Mating between two heterozygous animals (brothers and sisters) of the first filial generation (F1) of an outcross
Backcross Mating between one heterozygous animal of the first filial generation (F1) of an outcross and one homozygous animal of 
either one of the parental strains
Consomic Artificial inbred strain in which a whole chromosome is backcrossed from a donor strain to a host background
Congenic Artificial inbred strain in which a locus or a gene is backcrossed from a donor strain to a host background
Complementation Method to test the candidacy of a gene. In its classic form, can be performed by transgenic rescue of the phenotype or by 
generation of a knockout mouse for the mutated gene
In silico mapping Strategy to identify regions that are identical by descent between strains in which phylogenetic relationships have been 
established
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mouse genome sequence with a dense 
map of markers already genotyped for the 
majority of inbred strains require only in 
silico analyses without genotyping eﬀorts 
and with a resolution that can lead to the 
single gene.
In conclusion, even if the discovery of 
genes underlying QTLs has been proven 
to be extremely diﬃcult, recent advances 
in the mouse genome and the availabil-
ity of particular new mouse strains such 
as CSSs leave promising expectations for 
the near future. Moreover, the choice of 
using molecular phenotypes, such as the 
COLI kidney deposition, that are likely to 
be closer to pathogenic mechanisms rather 
than more complex clinical phenotypes 
such as proteinuria and renal failure, makes 
the trait chosen by Kato and colleagues7 a 
more tractable problem with high potential 
for shedding light on molecular pathways 
regulating the most important phenom-
enon in progression to end-stage renal 
failure: interstitial ﬁbrosis.
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Role for alkaline phosphatase 
as an inducer of vascular 
calcification in renal failure?
M Schoppet1 and CM Shanahan2
Vascular calcification is associated with increased cardiovascular 
morbidity and mortality. A number of calcification inhibitors have been 
defined recently, including inorganic pyrophosphate (PPi), an important 
physicochemical inhibitor of hydroxyapatite crystal growth. Increased 
hydrolysis of PPi by tissue-nonspecific alkaline phosphatase (TNAP) may 
occur in renal failure and act to enhance mineralization of vessels.
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Heterotopic, extraosseous vascular cal-
cification, a phenomenon known for 
decades, was once regarded as a passive 
physicochemical process triggered by 
excess calcium and phosphate exceeding 
the solubility threshold, resulting in pre-
cipitation and apatite mineral deposition 
in vessels and soft tissues. Over recent 
years, this concept has been challenged 
by a variety of in vitro and in vivo models 
of vascular calciﬁcation, especially tar-
geted gene deletion studies in animals, 
which have demonstrated that minerali-
zation is controlled by a balance between 
procalcific and anticalcific regulatory 
proteins acting locally in the vessel wall 
and/or systemically in the circulation. 
Alterations in this balance induced by 
injury, disease, or genetic deﬁciency are 
postulated to favor heterotopic mineral 
deposition.1 Further evidence support-
ing the hypothesis of calcification as 
an active, cell-mediated process comes 
from the observed similarities between 
vascular calciﬁcation and endochondral 
and intramembranous mineralization in 
bone. Thus, the molecular events induc-
ing extracellular matrix mineralization 
may be the same in both physiologi-
cal and pathological processes. Indeed, 
within calcifying vascular specimens, 
cells that are reminiscent of osteoblasts, 
chondrocytes, or osteoclasts have been 
detected, derived either from stem cells 
(circulating or local cells) or from pheno-
typic transdiﬀerentiation of vessel wall-
resident cells such as vascular smooth 
muscle cells. Furthermore, transcription 
factors and cytokines with crucial roles in 
bone homeostasis have been detected in 
calciﬁed vascular lesions,1 suggesting that 
mineralization of vessels may be triggered 
through similar molecular mechanisms 
and signaling pathways.
The study by Lomashvili et al.2 (this 
issue) has investigated the role of 
tissue-nonspeciﬁc alkaline phosphatase 
(TNAP) in the pathogenesis of vascu-
lar calciﬁcation. The authors show that 
TNAP is upregulated under uremic con-
ditions in vessels from rats, which leads 
to the hydrolysis and therefore inactiva-
tion of inorganic pyrophosphate (PPi), 
a potent inhibitor of hydroxyapatite 
crystal growth and a potential local and 
circulating inhibitor of vascular calciﬁ-
cation. Although the possibility that the 
TNAP/PPi system is involved in vascu-
lar calciﬁcation is intriguing, what is the 
evidence for its role or expression in the 
vascular system?
Firstly, the ectoenzymes PC-1/
nucleotide pyrophosphatase phospho-
diesterase 1 (NPP1), which hydrolyzes 
